caa a22 4500 606158251 CHVBK 20210128100618.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10557-014-6567-0 doi (NATIONALLICENCE)springer-10.1007/s10557-014-6567-0 Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy [Elektronische Daten] [Robert Rosenson, Michael Davidson, Ngoc-Anh Le, Jaime Burkle, Ray Pourfarzib] The inverse relationship between high-density lipoprotein cholesterol (HDL-C) concentrations and coronary heart disease risk is well established. As a result, in recent years there have been significant resources focused on identifying therapies that raise HDL-C and ultimately reduce cardiovascular events. Unfortunately, a number of trials aimed at increasing HDL-C have failed to show improved outcomes, and hence, have cast doubt on the importance of HDL-C as a therapeutic target. HDL-C, however, is only one measure of HDL. HDL levels can also been estimated by quantifying apolipoprotein A-I (apoA-I) levels using enzyme immunoassay or by measuring HDL particle number (HDL-P) using nuclear magnetic resonance spectroscopy (NMR) or ion mobility. While these surrogate measures are correlated, they are not comparable. Lipoprotein-altering therapies have been shown to have different effects on HDL-C, apoA-I and HDL-P and several studies have demonstrated that HDL-P is a stronger predictor of coronary heart disease risk than HDL-C and/or apoA-I. This paper will review available evidence supporting the use of HDL-P as the biomarker of choice to assess the contribution of HDL to cardiovascular risk and as the primary goal of HDL-raising therapies. Springer Science+Business Media New York, 2015 High density lipoprotein nationallicence High density lipoprotein particles nationallicence Cardiovascular disease nationallicence Atherosclerosis nationallicence High density lipoprotein raising therapies nationallicence Clinical trials nationallicence Prevention nationallicence Rosenson Robert Cardiometabolic Disorders Unit Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, 10029, New York, NY, USA aut Davidson Michael University of Chicago, 5841 S Maryland Ave, 60637, Chicago, IL, USA aut Le Ngoc-Anh Biomarker Core Laboratory Atlanta Research and Education Foundation, 1670 Clairmont Rd - Room 4A186, 30033, Decatur, GA, USA aut Burkle Jaime Piedmont Heart Institute, 1140 Hammond Drive. Building K. Suite 300, 30328, Atlanta, GA, USA aut Pourfarzib Ray LipoScience, Inc, 2500 Sumner Blvd, 27616, Raleigh, NC, USA aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/1(2015-02-01), 41-50 0920-3206 29:1<41 2015 29 10557 https://doi.org/10.1007/s10557-014-6567-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-014-6567-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rosenson Robert Cardiometabolic Disorders Unit Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, 10029, New York, NY, USA aut NATIONALLICENCE 700 1- Davidson Michael University of Chicago, 5841 S Maryland Ave, 60637, Chicago, IL, USA aut NATIONALLICENCE 700 1- Le Ngoc-Anh Biomarker Core Laboratory Atlanta Research and Education Foundation, 1670 Clairmont Rd - Room 4A186, 30033, Decatur, GA, USA aut NATIONALLICENCE 700 1- Burkle Jaime Piedmont Heart Institute, 1140 Hammond Drive. Building K. Suite 300, 30328, Atlanta, GA, USA aut NATIONALLICENCE 700 1- Pourfarzib Ray LipoScience, Inc, 2500 Sumner Blvd, 27616, Raleigh, NC, USA aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/1(2015-02-01), 41-50 0920-3206 29:1<41 2015 29 10557